Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial
Authors:
- 29 October 2022
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 174, 112-117
Abstract
No abstract availableKeywords
Funding Information
- Genentech
This publication has 10 references indexed in Scilit:
- Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative DurvalumabJAMA Network Open, 2022
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2022
- Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911LJournal of Thoracic Oncology, 2021
- Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II studyESMO Open, 2021
- Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in ProgressClinical Lung Cancer, 2021
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung CancerJAMA Oncology, 2021
- Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJournal of Thoracic Oncology, 2021
- Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)Journal of Thoracic Oncology, 2021
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLCJournal of Thoracic Oncology, 2020